-
Mashup Score: 36
This is a large multicentric global study combining a number of large national peritoneal surface oncology databases from three continents (39 centres) for
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 35
This is a large multicentric global study combining a number of large national peritoneal surface oncology databases from three continents (39 centres) for
Source: academic.oup.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Clinical Webinar Series - Gastrointestinal - 17 day(s) ago
Moderated by Dr. Hendifar, Cedars-Sinai and Dr. Lashkari, MOASC President and Oncologist at Wellness Oncology with discussants Jun Gong, MD, Cedars-Sinai and Zev Wainberg, MD, UCLA on the topic of Esophageal Cancer.
Source: moasc.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 36Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 - 1 month(s) ago
PURPOSE Despite fibroblast growth factor receptor (FGFR) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies. Subprotocol K1 (EAY131-K1) of the National Cancer Institute-MATCH platform trial was designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 amplification. METHODS EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of FGFR1-4 amplification in tumors. Patients with urothelial carcinoma were excluded. Enrolled patients received oral erdafitinib at a starting dose of 8 mg once daily continuously with escalation to 9 mg once daily continuously, on the basis of predefined time point assessments of phosphate levels, until disease progression or intolerable toxicity. The primary end point was centrally assessed objective response rate (ORR), with
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in tumors w/#FGFR1-4 amplifications, informative that not all #FGFR alterations may be targetable https://t.co/HBd09KLaAT @OncoAlert @JCO_ASCO @ASCOPost https://t.co/7LooXN8p7g
-
-
Mashup Score: 36Phase II Study of Erdafitinib in Patients With Tumors With FGFR Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1 - 1 month(s) ago
PURPOSE Despite fibroblast growth factor receptor (FGFR) inhibitors being approved in tumor types with select FGFR rearrangements or gene mutations, amplifications of FGFR represent the most common FGFR alteration across malignancies. Subprotocol K1 (EAY131-K1) of the National Cancer Institute-MATCH platform trial was designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 amplification. METHODS EAY131-K1 was an open-label, single-arm, phase II study with central confirmation of presence of FGFR1-4 amplification in tumors. Patients with urothelial carcinoma were excluded. Enrolled patients received oral erdafitinib at a starting dose of 8 mg once daily continuously with escalation to 9 mg once daily continuously, on the basis of predefined time point assessments of phosphate levels, until disease progression or intolerable toxicity. The primary end point was centrally assessed objective response rate (ORR), with
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
2/2 Dual publication @JCOPO_ASCO @theNCI @eaonc NCI-MATCH Subprotocol K1 PhII trial ➡️ no activity (0% ORR) of #Erdafitinib in tumors w/#FGFR1-4 amplifications, informative that not all #FGFR alterations may be targetable https://t.co/HBd09KLaAT @OncoAlert @JCO_ASCO @ASCOPost https://t.co/7LooXN8p7g
-
-
Mashup Score: 26
PURPOSE Subprotocol K2 (EAY131-K2) of the NCI-MATCH platform trial was an open-label, single-arm, phase II study designed to evaluate the antitumor efficacy of the oral FGFR1-4 inhibitor, erdafitinib, in patients with tumors harboring FGFR1-4 mutations or fusions. METHODS Central confirmation of tumor FGFR1-4 mutations or fusions was required for outcome analysis. Patients with urothelial carcinoma were excluded. Enrolled subjects received oral erdafitinib at a starting dose of 8 mg daily continuously until intolerable toxicity or disease progression. The primary end point was objective response rate (ORR) with key secondary end points of safety, progression-free survival (PFS), and overall survival (OS). RESULTS Thirty-five patients were enrolled, and 25 patients were included in the primary efficacy analysis as prespecified in the protocol. The median age was 61 years, and 52% of subjects had received ≥3 previous lines of therapy. The confirmed ORR was 16% (4 of 25 [90% CI, 5.7 to 33
Source: ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Treatment with 177Lu-Dotatate resulted in markedly longer progression-free survival and a significantly higher response rate than high-dose octreotide LAR among patients with advanced midgut neuroendocrine tumors. Preliminary evidence of an overall survival benefit was seen in an interim …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet-
Highlighting seminal work from #KOL speakers at the 5th Annual @CSCancerCenter GI Tumor Conf: Dr. Wolin: NETTER-1 & CLARINET in #NETs https://t.co/wSon3VVrfG https://t.co/TmAJi7Xzhf @LACNETS @NANETS1 Mar 23, 2024. Register at https://t.co/8thoQRicGm @OncoAlert @CMECedarsSinai https://t.co/0gnagmbbqr
-
-
Mashup Score: 16The Molecular Twin artificial-intelligence platform integrates multi-omic data to predict outcomes for pancreatic adenocarcinoma patients - PubMed - 2 month(s) ago
Contemporary analyses focused on a limited number of clinical and molecular biomarkers have been unable to accurately predict clinical outcomes in pancreatic ductal adenocarcinoma. Here we describe a precision medicine platform known as the Molecular Twin consisting of advanced machine-learning mode …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 7Modulating the therapeutic response of tumours to dietary serine and glycine starvation - PubMed - 2 month(s) ago
The non-essential amino acids serine and glycine are used in multiple anabolic processes that support cancer cell growth and proliferation (reviewed in ref. 1). While some cancer cells upregulate de novo serine synthesis, many others rely on exogenous serine for optimal growth. Restriction of dietar …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet-
Highlighting seminal work from #KOL speakers at the 5th Annual @CSCancerCenter GI Tumor Conf: Dr. Oliver Maddocks: #aminoacid restriction as a novel #PDAC therapeutic strategy https://t.co/XIp56h9OnN Mar 23, 2024. Register at https://t.co/8thoQRicGm @OncoAlert @CMECedarsSinai https://t.co/fzkmEB8zzU
-
-
Mashup Score: 9Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma - PubMed - 2 month(s) ago
KRAS WT PDAC represents 10.7% of PDAC and is enriched with targetable alterations, including immuno-oncologic markers. Identification of KRAS WT patients in clinical practice may expand therapeutic options in a clinically meaningful manner.
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
RT @BjsOpen: Hyperthermic intraperitoneal chemotherapy in colorectal cancer ➡️https://t.co/lR7z5BeuG1 This is a large multicentric global…